Solara Active Pharma Ltd board approves rights issue of Rs 450 crores equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
The Board of Directors of Solara Active Pharma Sciences Limited, at its meeting held today have approved the financial results of the company for the period ended March 31, 2023 - Q4FY23 and FY2023.
Solara Active Pharma Sciences Ltd announced the successful completion EU-GMP Inspection, carried out jointly by the SUKL, Ministry of Health of the Czech Republic and INFARMED, Portugal at the multi-product manufacturing facility at Cuddalore.
According to the findings of a new Future Market Insights (FMI) report, the global Ibuprofen API Market crossed US$ 626.2 Million in 2022 and is expected to grow at a CAGR of 3% to reach US$ 772.2 Million by 2029. The key drivers of the Ibuprofen API market are the ongoing need for low-cost nonsteroidal anti-inflamm.
Solara Active Pharma Sciences Ltd today announced that its new state-of-the-art multipurpose API manufacturing facility at Visakhapatnam, Andhra Pradesh completed successfully the inspection carried out by the US FDA.